Moderna's Canadian Double Approval and Veteran Study Data Point to a Broadening Pipeline
Published on 11/12/2026 at 03:11 | Editorial boerse-global.de
Moderna's case no longer rests on a single product line. Within three days this month the vaccine maker logged a regulatory first in Canada, fresh observational data on its next-generation COVID shot, an early cancer signal and a disclosed setback — a spread of news that says as much about the breadth of its pipeline as about any one asset.
A Canadian first for the flu franchise
Health Canada's November 5 decision cleared both mFLUSIVA, a seasonal influenza vaccine, and mCOFLU, a combined influenza/COVID-19 shot, for adults aged 50 and older. Canada became the first country to approve either product. Moderna said it will work with Canadian health authorities and immunization partners on future availability.
The approvals give the company's respiratory portfolio a concrete regulatory foothold beyond COVID-19. What they are worth commercially will hinge on how the rollout is executed.
Veteran data: a 35.9% and a 47.0% gap
Moderna announced publication in JAMA Network Open of an observational study comparing mNEXSPIKE with Comirnaty under real-world conditions. The analysis covered 294,499 matched U.S. veterans aged 65 and older.
Should investors sell immediately? Or is it worth buying Moderna?
Against medically treated COVID-19 illness, mNEXSPIKE showed a relative vaccine effectiveness of 35.9% versus Comirnaty. For COVID-related hospitalizations the figure was 47.0%. That second endpoint is the more striking of the two, pointing to a tangible health benefit for the older group studied.
Moderna itself flagged the limits of the design, including the possibility that residual confounders skewed the results. The numbers describe an observed association between the vaccine used and the outcomes tracked — not a proven causal advantage. Both readings have to be held together: the potential commercial value of a product edge, and the methodological caution that comes with observational evidence.
An early myeloma signal, and a norovirus stumble
On November 4 the company reported first data for mRNA-2808 in relapsed or refractory multiple myeloma. Four confirmed responses were observed among eleven patients evaluable for response. The cohort is small, which argues for restraint, but it is a development signal worth tracking. Updated results are due at the ASH conference from December 12 to 15 — a concrete checkpoint for whether the early impression holds.
The pipeline also has to absorb disappointment. According to media reports, Moderna said on November 6 that it would not test an additional cohort this season for its norovirus candidate, after an interim analysis missed the statistical threshold for early success. That cuts against any blanket assumption of success across the development portfolio, and it is precisely why the wider spread of programs matters: the quality of the setup shows in whether progress elsewhere survives a miss.
What analysts are watching
The Overweight rating on the stock was maintained, with the research house citing third-quarter product sales, a raised revenue growth outlook and the company's liquidity position as grounds.
Moderna at a turning point? This analysis reveals what investors need to know now.
Moderna's analyst day is scheduled for November 12, 2026, a date the company lists in its earnings release filed with the U.S. Securities and Exchange Commission.
The overall picture leans cautiously positive. Real-world data, the Canadian approvals and early clinical signals together suggest more substance than a single headline can capture. That view holds only as long as each advance is weighed at its actual stage of maturity — and the clinical updates now on the calendar will set the next substantive benchmark.
Ad
Moderna Stock: New Analysis - 12 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
